Get the Stockscreener App
7.70
2.65%
-0.21
Pre-market:
7.81
0.11
+1.43%
Dogwood Therapeutics Inc stock is traded at $7.70, with a volume of 615.48K.
It is down -2.65% in the last 24 hours and up +55.24% over the past month.
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
See More
Previous Close:
$7.91
Open:
$7.88
24h Volume:
615.48K
Relative Volume:
0.91
Market Cap:
$14.72M
Revenue:
-
Net Income/Loss:
$-5.73M
P/E Ratio:
-1.1756
EPS:
-6.55
Net Cash Flow:
$-4.13M
1W Performance:
+53.01%
1M Performance:
+55.24%
6M Performance:
+53.69%
1Y Performance:
+0.00%
1-Day Range:
$7.46
$8.10
1-Week Range:
$4.92
$9.50
52-Week Range:
$1.62
$29.28
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Name
Dogwood Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Compare DWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
7.70 | 15.12M | 0 | -5.73M | -4.13M | -6.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Dogwood Therapeutics Inc Stock (DWTX) Latest News
Dogwood Therapeutics stock price target raised to $12 from $10 at H.C. Wainwright - Investing.com
What data driven models say about Dogwood Therapeutics Inc.’s futureEarnings Recap Report & Fast Gain Stock Trading Tips - newser.com
Is this a good reentry point in Dogwood Therapeutics Inc.July 2025 PostEarnings & Weekly Chart Analysis and Guides - newser.com
Using RSI to spot recovery in Dogwood Therapeutics Inc.Quarterly Market Summary & Risk Controlled Daily Trade Plans - newser.com
Will Dogwood Therapeutics Inc. stock reach all time highs in 2025Weekly Loss Report & Weekly Hot Stock Watchlists - newser.com
Will Dogwood Therapeutics Inc. price bounce be sustainable2025 Trade Ideas & Smart Swing Trading Techniques - newser.com
Dogwood Therapeutics, Inc. (DWTX) Stock: Skyrockets as NCI-Backed SP16 Deal Sparks Investor Confidence - parameter.io
Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug - Stocktwits
Dogwood Therapeutics stock soars after securing cancer pain treatment license - Investing.com UK
DWTX Stock Surge: Must-Know Insights - StocksToTrade
How high can Dogwood Therapeutics Inc. stock goPortfolio Value Summary & Stepwise Trade Execution Plans - newser.com
Dogwood Therapeutics Stock Skyrockets: Too Late to Buy? - timothysykes.com
Dogwood Therapeutics : Corporate Presentation (Investor Meeting Presentation Sept 29 2025) - MarketScreener
Dogwood Therapeutics Secures Licensing Deal with Serpin Pharma - TipRanks
Dogwood Therapeutics licenses SP16 for chemotherapy neuropathy treatment - Investing.com India
Dogwood Therapeutics licenses SP16 for chemotherapy neuropathy treatment By Investing.com - Investing.com Australia
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer P - GlobeNewswire
Dogwood Therapeutics Incsecures royalty-free license for Sp16 in all-stock deal with Serpin Pharma - MarketScreener
Detecting price anomalies in Dogwood Therapeutics Inc. with AIPortfolio Return Report & Verified High Yield Trade Plans - newser.com
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty - GlobeNewswire
NCI-Backed First-in-Class Cancer Pain Drug: Dogwood Therapeutics Lands Global Rights to SP16 Treatment - Stock Titan
Will Dogwood Therapeutics Inc. stock benefit from sector rotationJuly 2025 Big Picture & Expert Curated Trade Setup Alerts - newser.com
Is Dogwood Therapeutics Inc a good long term investmentSector ETF Performance & High Return Investment Plans - earlytimes.in
What drives Dogwood Therapeutics Inc stock priceStochastic Oscillator Alerts & Superior Trading Portfolio - earlytimes.in
Dogwood Therapeutics Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Fast Profit Trading Tips - Early Times
Dogwood Therapeutics Inc Stock (DWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):